Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted to SN‑38 inside cancer cells. SN‑38 binds to the DNA‑topoisomerase I complex, preventing the re‑ligation of single‑strand DNA breaks, which leads to accumulation of DNA damage and ultimately cell death.

The specific dose of Irinotecan Kabi is determined by the prescribing oncologist based on factors such as patient weight, disease stage, and treatment protocol. Only a qualified healthcare professional should set the dosing schedule.

Irinotecan is classified as contraindicated in pregnancy because it may cause fetal harm. It is also not recommended while breastfeeding, as it can be excreted in milk and affect the infant. Consultation with a specialist is essential.

To place an order, submit an enquiry on the Irinotecan Kabi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. When combined with fluoropyrimidines, it provides a survival benefit comparable to other combination regimens, but its toxicity profile—particularly diarrhea and neutropenia—differs and requires specific management.

Irinotecan Kabi should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the product from light, moisture, and extreme temperature fluctuations. Follow aseptic techniques when preparing the infusion solution.

Irinotecan Kabi is given by intravenous infusion, typically over 30 to 90 minutes depending on the prescribed regimen. The infusion is performed in a clinical setting by qualified healthcare personnel, with monitoring for infusion‑related reactions.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, hepatic toxicity, and rare anaphylactic reactions. Prompt recognition and supportive care are essential to mitigate these complications.

Patients with known hypersensitivity to Irinotecan or its excipients, those with uncontrolled infections, severe hepatic impairment, or a history of bowel obstruction should not receive Irinotecan. Additionally, pregnant women and nursing mothers are contraindicated.